We've had Eye's On the JP Morgan Healthcare Conference, Lifesciences 2024 restructuring stats, and some new drug development partnerships.

According to an annual PwC study released in December, the amount of M&A activity in the pharmaceutical and life sciences sectors in 2024...

Check out the final listings of FDA NDA and BLA approvals for 2024.

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

This week, we had eyes on data readouts, launch metrics, M&A, and more. Catch up with the news from Roche, AstraZeneca, Lundbeck, and AbbVie

We've had Eyes On some of the recent deals, results, and investor actions. Check out the happenings at Sanofi/Opella, Pfizer, Regeneron, and